Guillaume Mestrallet

Dr. Guillaume Mestrallet

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
GMGuillaume Mestrallet
Guillaume Mestrallet
MBMatthew Brown
Matthew Brown
CBCansu Cimen Bozkus
Cansu Cimen Bozkus
NBNina Bhardwaj
Nina Bhardwaj
Up to 30% of colorectal, endometrial and gastric cancers have a deficiency in mismatch repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients with Lynch Syndrome who inherit an inactive MMR allele have an up to 80% risk for developing a mismatch repair deficient (MMRd) cancer. Due to an inability to repair DNA, MMRd tumors present with genomic instability in microsatellite regions (MS). Tumors with high MS instability (MSI-H) are characterized by an increased frequency of insertion/deletions (indels) that can encode novel neoantigens if they occur in coding regions. The high tumor antigen burden for MMRd cancers is accompanied by an inflamed tumor microenvironment (TME) that contributes to the clinical effectiveness of anti-PD-1 therapy in this patient population. However, between 40 and 70% of MMRd cancer patients do not respond to treatment with PD-1 blockade, suggesting that tumor-intrinsic and -extrinsic resistance mechanisms may affect the success of checkpoint blockade. Immune evasion mechanisms that occur during early tumorigenesis and persist through cancer development may provide a window into resistance pathways that limit the effectiveness of anti-PD-1 therapy. Here, we review the mechanisms of immune escape in MMRd tumors during development and checkpoint blockade treatment, including T cell dysregulation and myeloid cell-mediated immunosuppression in the TME. Finally, we discuss the development of new therapeutic approaches to tackle resistance in MMRd tumors, including cancer vaccines, therapies targeting immunosuppressive myeloid programs, and immune checkpoint combination strategies.

6 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
GMGuillaume Mestrallet
Guillaume Mestrallet
KSKazuki Sone
Kazuki Sone
NBNina Bhardwaj
Nina Bhardwaj
Dendritic cells (DCs) play a key role to modulate anti-cancer immunity in the tumor microenvironment (TME). They link innate to adaptive immunity by processing and presenting tumor antigens to T cells thereby initiating an anti-tumor response. However, subsets of DCs also induce immune-tolerance, leading to tumor immune escape. In this regard, the TME plays a major role in adversely affecting DC function. Better understanding of DC impairment mechanisms in the TME will lead to more efficient DC-targeting immunotherapy. Here, we review the different subtypes and functions of DCs in the TME, including conventional DCs, plasmacytoid DC and the newly proposed subset, mregDC. We further focus on how cancer cells modulate DCs to escape from the host’s immune-surveillance. Immune checkpoint expression, small molecule mediators, metabolites, deprivation of pro-immunogenic and release of pro-tumorigenic cytokine secretion by tumors and tumor-attracted immuno-suppressive cells inhibit DC differentiation and function. Finally, we discuss the impact of established therapies on DCs, such as immune checkpoint blockade. Creative DC-targeted therapeutic strategies will be highlighted, including cancer vaccines and cell-based therapies.

6 December 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
GMGuillaume Mestrallet
Guillaume Mestrallet
NRNathalie Rouas-Freiss
Nathalie Rouas-Freiss
JLJoel LeMaoult
Joel LeMaoult
Nicolas FortunelNicolas Fortunel
Nicolas Fortunel
Michele T MartinMichele T Martin
Michele T Martin
Although the role of epidermal cells in skin regeneration has been extensively documented, their functions in immunity and tolerance mechanisms are largely underestimated. The aim of the present review was to outline the state of knowledge on resident immune cells of hematopoietic origin hosted in the epidermis, and then to focus on the involvement of keratinocytes in the complex skin immune networks acting in homeostasis and regeneration conditions. Based on this knowledge, the mechanisms of immune tolerance are reviewed. In particular, strategies based on immunosuppression mediated by HLA-G are highlighted, as recent advances in this field open up perspectives in epidermis-substitute bioengineering for temporary and permanent skin replacement strategies.

12 December 2019 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
JDJérémy Dufloo
Jérémy Dufloo
FGFlorence Guivel‐Benhassine
Florence Guivel‐Benhassine
JBJulian Buchrieser
Julian Buchrieser
VLValérie Lorin
Valérie Lorin
LGLudivine Grzelak
Ludivine Grzelak
OSOlivier Schwartz
Olivier Schwartz

28 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LLLeonard Lugand
Leonard Lugand
GMGuillaume Mestrallet
Guillaume Mestrallet
RLRebecca Laboureur
Rebecca Laboureur
CDClement Dumont
Clement Dumont
FBFatiha Bouhidel
Fatiha Bouhidel
JLJoel LeMaoult
Joel LeMaoult
Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost in the classically used 2D models along with their relative simplicity and handiness have made them the most studied 3D tumor model. Their application as a theranostic tool or as a means to study tumor-host interaction is now well-established in various cancers. However, their use in the field of Renal Cell Carcinoma (RCC) remains very limited. The aim of this work is to present methods to implement a basic RCC spheroid model. These methods cover the steps from RCC tumor dissociation to spheroid infiltration by immune cells. We present a protocol for RCC dissociation using Liberase TM and introduce a culture medium containing Epithelial Growth Factor and Hydrocortisone allowing for faster growth of RCC primary cells. We show that the liquid overlay technique allows for the formation of spheroids from cell lines and from primary cultures. We present a method using morphological criteria to select a homogeneous spheroid population based on a Fiji macro. We then show that spheroids can be infiltrated by PBMCs after activation with OKT3 or IL-15. Finally, we provide an example of application by implementing an immune spheroid killing assay allowing observing increased spheroid destruction after treatment with PD-1 inhibitors. Thus the straightforward methods presented here allow for efficient spheroid formation for a simple RCC 3D model that can be standardized and infused with immune cells to study immunotherapies.

8 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
GMGuillaume Mestrallet
Guillaume Mestrallet
FAFrédéric Auvré
Frédéric Auvré
CSChantal Schenowitz
Chantal Schenowitz
ECEdgardo D. Carosella
Edgardo D. Carosella
JLJoel LeMaoult
Joel LeMaoult
Nicolas FortunelNicolas Fortunel
Nicolas Fortunel
Human skin protects the body against infection and injury. This protection involves immune and epithelial cells, but their interactions remain largely unknown. Here, we show that cultured epidermal keratinocytes inhibit allogenic CD4+ T-cell proliferation under both normal and inflammatory conditions. Inhibition occurs through the secretion of soluble factors, including TGFB1 and the cell-surface expression of HLA-G1 and PD-L1 immune checkpoints. For the first time, we here describe the expression of the HLA-G1 protein in healthy human skin and its role in keratinocyte-driven tissue immunomodulation. The overexpression of HLA-G1 with an inducible vector increased the immunosuppressive properties of keratinocytes, opening up perspectives for their use in allogeneic settings for cell therapy.